Molecular Evolution of Ear ly-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories Graphical

[1]  S. Fröhling,et al.  Analysis of mutational signatures with yet another package for signature analysis , 2020, Genes, chromosomes & cancer.

[2]  Natalie S. Fox,et al.  The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression , 2018, Cell.

[3]  J. Weinstein,et al.  A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. , 2018, Cell.

[4]  Christoph Plass,et al.  Enrichment analysis with EpiAnnotator , 2018, Bioinform..

[5]  Y. Shin,et al.  ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cells , 2017, Oncogenesis.

[6]  C. Boerkoel,et al.  FOXP1 haploinsufficiency: Phenotypes beyond behavior and intellectual disability? , 2017, American journal of medical genetics. Part A.

[7]  J. Korbel,et al.  Genomes of early onset prostate cancer , 2017, Current opinion in urology.

[8]  D. Strand,et al.  OMIP‐040: Optimized gating of human prostate cellular subpopulations , 2017, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[9]  Takafumi N. Yamaguchi,et al.  TMPRSS2–ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer , 2017, Nature Genetics.

[10]  Stefan J. Barfeld,et al.  Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. , 2017, Cell reports.

[11]  Michael P. Schroeder,et al.  Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations , 2017, Genome Medicine.

[12]  K. Cooney,et al.  Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. , 2017, European urology.

[13]  Min A. Jhun,et al.  Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort , 2017, Oncotarget.

[14]  Stefan J. Barfeld,et al.  c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks , 2017, EBioMedicine.

[15]  Shijie C. Zheng,et al.  Cell-type deconvolution in epigenome-wide association studies: a review and recommendations. , 2017, Epigenomics.

[16]  D. Neal,et al.  Asporin is a stromally expressed marker associated with prostate cancer progression , 2017, British Journal of Cancer.

[17]  Alain Bergeron,et al.  Genomic hallmarks of localized, non-indolent prostate cancer , 2017, Nature.

[18]  F. Orso,et al.  The RNA-binding protein ESRP1 promotes human colorectal cancer progression , 2016, Oncotarget.

[19]  Bin Zhu,et al.  Edinburgh Research Explorer Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors , 2022 .

[20]  Nancy R. Zhang,et al.  Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing , 2016, Proceedings of the National Academy of Sciences.

[21]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[22]  Neva C. Durand,et al.  Juicer Provides a One-Click System for Analyzing Loop-Resolution Hi-C Experiments. , 2016, Cell systems.

[23]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[24]  Jeffrey M. Bhasin,et al.  Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer. , 2015, Cell reports.

[25]  A. Butte,et al.  Systematic pan-cancer analysis of tumour purity , 2015, Nature Communications.

[26]  Kin Chan,et al.  Clusters of Multiple Mutations: Incidence and Molecular Mechanisms. , 2015, Annual review of genetics.

[27]  M. Stratton,et al.  Clock-like mutational processes in human somatic cells , 2015, Nature Genetics.

[28]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[29]  Paola Lecca,et al.  Defining order and timing of mutations during cancer progression: the TO-DAG probabilistic graphical model , 2015, Front. Genet..

[30]  Gad Getz,et al.  An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers , 2015, Nature Genetics.

[31]  W. Kraus,et al.  groHMM: a computational tool for identifying unannotated and cell type-specific transcription units from global run-on sequencing data , 2015, BMC Bioinformatics.

[32]  C. Swanton,et al.  APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. , 2015, Cancer discovery.

[33]  Faraz Hach,et al.  Spatial genomic heterogeneity within localized, multifocal prostate cancer , 2015, Nature Genetics.

[34]  Neva C. Durand,et al.  A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping , 2014, Cell.

[35]  Dmitry A. Gordenin,et al.  Hypermutation in human cancer genomes: footprints and mechanisms , 2014, Nature Reviews Cancer.

[36]  Thomas Lengauer,et al.  Comprehensive Analysis of DNA Methylation Data with RnBeads , 2014, Nature Methods.

[37]  K. Miyazawa,et al.  Epithelial Splicing Regulatory Proteins 1 (ESRP1) and 2 (ESRP2) Suppress Cancer Cell Motility via Different Mechanisms* , 2014, The Journal of Biological Chemistry.

[38]  Giancarlo Mauri,et al.  CAPRI: Efficient Inference of Cancer Progression Models from Cross-sectional Data , 2014, bioRxiv.

[39]  Amos Tanay,et al.  Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. , 2014, Cell reports.

[40]  Peter A. Jones,et al.  Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer , 2014, Genome research.

[41]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[42]  R. Young,et al.  Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.

[43]  Thomas Whitington,et al.  Transcription Factor Binding in Human Cells Occurs in Dense Clusters Formed around Cohesin Anchor Sites , 2013, Cell.

[44]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[45]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[46]  J. Korbel,et al.  Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.

[47]  D. Zheng,et al.  ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.

[48]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[49]  V. Beneš,et al.  Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.

[50]  Martin J. Aryee,et al.  DNA Methylation Alterations Exhibit Intraindividual Stability and Interindividual Heterogeneity in Prostate Cancer Metastases , 2013, Science Translational Medicine.

[51]  R. Weksberg,et al.  Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray , 2013, Epigenetics.

[52]  D. Rowley,et al.  The reactive stroma microenvironment and prostate cancer progression. , 2012, Endocrine-related cancer.

[53]  M. Rubin,et al.  Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. , 2012, Cancer discovery.

[54]  V. Beneš,et al.  DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..

[55]  Steven A. Roberts,et al.  Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. , 2012, Molecular cell.

[56]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[57]  Devin C. Koestler,et al.  DNA methylation arrays as surrogate measures of cell mixture distribution , 2012, BMC Bioinformatics.

[58]  Manolis Kellis,et al.  ChromHMM: automating chromatin-state discovery and characterization , 2012, Nature Methods.

[59]  T. H. van der Kwast,et al.  NKX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy , 2011, Clinical Cancer Research.

[60]  I. Mills,et al.  The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis , 2011, The EMBO journal.

[61]  M. Delorenzi,et al.  Identification of Prognostic Molecular Features in the Reactive Stroma of Human Breast and Prostate Cancer , 2011, PloS one.

[62]  C. Glass,et al.  Reprogramming Transcription via Distinct Classes of Enhancers Functionally Defined by eRNA , 2011, Nature.

[63]  T. Russo,et al.  Direct targets of Klf5 transcription factor contribute to the maintenance of mouse embryonic stem cell undifferentiated state , 2010, BMC Biology.

[64]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[65]  Francesca Demichelis,et al.  Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.

[66]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[67]  Aaron R. Quinlan,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[68]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[69]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[70]  J. Wang-Rodriguez,et al.  In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[71]  Ron Shamir,et al.  CLICK and EXPANDER: a system for clustering and visualizing gene expression data , 2003, Bioinform..

[72]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Olivier Gascuel,et al.  Fast and Accurate Phylogeny Reconstruction Algorithms Based on the Minimum-Evolution Principle , 2002, WABI.

[74]  T. Stamey,et al.  Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. , 2002, Urology.

[75]  D. Chan,et al.  Natural History of Progression After PSA Elevation Following Radical Prostatectomy , 1999 .

[76]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[77]  H. Huland,et al.  Numerical chromosomal aberrations in transition-zone carcinomas of the prostate. , 1997, The Journal of urology.